Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 16:00 save search
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.94 -1.24% -1.26% 710K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.41 4.44% 4.26% 2.3M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Published: 2024-04-02 (Crawled : 16:00) - biospace.com/
KRBP | $2.3 -90.21% 15K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.0%
favorable biopharma trial
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Published: 2024-03-28 (Crawled : 16:00) - biospace.com/
KPRX | $0.4913 -2.94% -3.03% 160K
|
Manufacturing
|
| O: -2.26%
H: 20.0%
C: 17.67%
pharmaceuticals meeting trial
Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-03-25 (Crawled : 16:00) - prnewswire.com
TMO | News | $541.52 -1.05% 0.61% 2.1M
|
Health Technology
|
| O: 0.02%
H: 0.31%
C: -1.65%
INFY | $16.51 -2.6% -0.18% 31M
|
Technology Services
|
| O: 0.4%
H: 0.0%
C: -0.9%
CTLT | $55.8 -0.29% 0.0% 1M
|
Health Technology
|
| O: 0.54%
H: 0.82%
C: 0.55%
ICLR | $291.74 -0.1% -0.1% 500K
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.68%
report reach trial market
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SONN | $1.7 -6.47% 17K
|
Health Technology
|
| O: 10.81%
H: 7.8%
C: 0.98%
son-080 trial
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
ATNM | $6.67 -8.0% 1.2% 420K
|
Health Technology
|
| O: 2.04%
H: 19.98%
C: 18.71%
active aml trial
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
STTK | $10.11 0.9% 0.89% 430K
|
Health Technology
|
| O: 107.58%
H: 23.74%
C: 10.96%
sl-1721 positive ongoing expansion topline trial
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
VSTM | $10.19 -6.0% -6.38% 67K
|
Health Technology
|
| O: -0.14%
H: 10.83%
C: 10.83%
avutometinib cancer defactinib trial
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Published: 2023-11-28 (Crawled : 16:00) - globenewswire.com
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -1.55%
H: 12.83%
C: 10.47%
piter-02 association positive publication treatment medical trial results
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
CADL | $5.49 0.92% 0.91% 740K
|
|
| O: 4.63%
H: 2.0%
C: -24.97%
can-2409 positive cancer pancreatic trial therapeutics
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
RAPT | $7.94 -1.24% -1.26% 710K
|
Health Technology
|
| O: 1.97%
H: 12.63%
C: 6.97%
flx475 positive trial therapeutics response
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
MOLN | $3.67 -3.42% -3.54% 320
|
Professional, Scientific, and T...
|
| O: 0.72%
H: 9.74%
C: 9.74%
mp0317 tumors positive ongoing meeting trial molecular
City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients
Published: 2023-10-03 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 34K
|
Communications
| Email alert
Add to watchlist
breast hope cancer city trial
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
Published: 2023-09-11 (Crawled : 16:00) - globenewswire.com
VIGL | $2.75 -5.82% -6.18% 50K
|
|
| O: 0.0%
H: 7.6%
C: 1.46%
vgl101 association meeting neurological trial
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
Published: 2023-09-05 (Crawled : 16:00) - biospace.com/
WVE | $4.8 0.21% 0.21% 540K
|
Health Technology
|
| O: 4.19%
H: 2.54%
C: -5.92%
wve-006 life sciences application trial submission
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
RDHL | $0.4301 11.57% 10.37% 660K
|
Health Technology
|
| O: 1.56%
H: 4.62%
C: -1.54%
rhb-107 covid-19 fda cleared trial platform
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2023-07-31 (Crawled : 16:00) - biospace.com/
RARE F | $43.38 -1.65% -1.68% 770K
|
Health Technology
|
| O: 0.81%
H: 1.93%
C: -0.78%
ux701 disease treatment trial therapy
ADDF Statement on New Results from Donanemab's TRAILBLAZER-ALZ 2 Trial
Published: 2023-07-17 (Crawled : 16:00) - prnewswire.com
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.0%
H: 0.26%
C: -0.51%
trial results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.